Pediatric infratentorial ependymoma: Prognostic significance of anaplastic histology

Journal of Neuro-Oncology

Volumn 106, Issue 3, 2012, Pages 619-626

  Phi, Ji Hoon ^a   Wang, Kyu Chang ^a   Park, Sung Hye ^b   Kim, Il Han ^b,c   Kim, In One ^b   Park, Kyung Duk ^a   Ahn, Hyo Seop ^a,c   Lee, Ji Yeoun ^a   Son, Young Je ^d   Kim, Seung Ki ^a  

^a Seoul National University Children's Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

Author keywords

Anaplastic histology; Children; Ependymoma; Prognosis; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; KI 67 ANTIGEN; METHOTREXATE; VINCRISTINE;

ARTICLE; BRAIN RADIATION; BRAIN STEM TUMOR; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; EPENDYMOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFANT; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSTERIOR CRANIAL FOSSA TUMOR; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; PROTON THERAPY; RADIATION DOSE; RADIOSURGERY; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; ELECTRONIC HEALTH RECORDS; EPENDYMOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFRATENTORIAL NEOPLASMS; KI-67 ANTIGEN; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84860410350     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0699-x     Document Type: Article

References (33)

1. Tamburrini G, D'Ercole M, Pettorini BL, Caldarelli M, Massimi L, Di Rocco C (2009) Survival following treatment for intracranial ependymoma: a review. Childs Nerv Syst 25: 1303-1312. doi: 10.1007/s00381-009-0874-y
2. Shu HK, Sall WF, Maity A, Tochner ZA, Janss AJ, Belasco JB, Rorke-Adams LB, Phillips PC, Sutton LN, Fisher MJ (2007) Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer 110: 432-441. doi: 10.1002/cncr. 22782 (Pubitemid 47121905)
3. van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, Sainte-Rose C, Zerah M, Thorne J, Renier D (2002) Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 97: 827-835. doi: 10.3171/jns.2002.97.4.0827 (Pubitemid 35222404)
4. McGuire CS, Sainani KL, Fisher PG (2009) Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer 52: 65-69. doi: 10.1002/pbc.21806
5. Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, Cornell CJ, Link M, Luthy AR, Camitta B (1991) Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 74: 905-909
6. Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL et al (1990) The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72: 572-582 (Pubitemid 20113683)
7. Gandola L, Massimino M, Cefalo G, Solero C, Spreafico F, Pecori E, Riva D, Collini P, Pignoli E, Giangaspero F, Luksch R, Berretta S, Poggi G, Biassoni V, Ferrari A, Pollo B, Favre C, Sardi I, Terenziani M, Fossati-Bellani F (2009) Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 27: 566-571. doi: 10.1200/jco. 2008.18.4176
8. Ikezaki K, Matsushima T, Inoue T, Yokoyama N, Kaneko Y, Fukui M (1993) Correlation of microanatomical localization with postoperative survival in posterior fossa ependymomas. Neurosurgery 32: 38-449.
9. Ginguene C, Champier J, Maallem S, Strazielle N, Jouvet A, Fevre-Montange M, Ghersi-Egea JF (2010) P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol 20: 926-935. doi: 10.1111/j.1750-3639.2010. 00389.x
10. Kim SK, Lim SY, Wang KC, Kim YY, Chi JG, Choi YL, Shin HJ, Cho BK (2004) Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro. Oncol Rep 12: 403-409
11. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, Lyon
12. Perilongo G, Massimino M, Sotti G, Belfontali T, Masiero L, Rigobello L, Garre L, Carli M, Lombardi F, Solero C, Sainati L, Canale V, del Prever AB, Giangaspero F, Andreussi L, Mazza C, Madon E (1997) Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neurooncology Group. Med Pediatr Oncol 29: 79-85 (Pubitemid 27242225)
13. Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, Janosky J, Deutsch M (1995) Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 37: 655-666
14. Robertson PL, Zeltzer PM, Boyett JM, Rorke LB, Allen JC, Geyer JR, Stanley P, Li H, Albright AL, McGuire-Cullen P, Finlay JL, Stevens KR Jr, Milstein JM, Packer RJ, Wisoff J (1998) Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 88: 695-703. doi: 10.3171/jns.1998.88.4.0695 (Pubitemid 28145213)
15. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schottler A, Kulozik AE, Witt O, von Deimling A, Lichter P, Pfister S (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28: 3182-3190. doi: 10.1200/jco.2009.27.3359
16. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, Janssen I, Giangaspero F, Forni M, Finocchiaro G, Genitori L, Giordano F, Riccardi R, Schoenmakers EF, Massimino M, Sozzi G (2006) Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 24: 5223-5233. doi: 10.1200/jco.2006.06. 3701 (Pubitemid 46631366)
17. Korshunov A, Golanov A, Sycheva R, Timirgaz V (2004) The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 100: 1230-1237. doi: 10.1002/ cncr.20075 (Pubitemid 38325952)
18. Thorarinsdottir HK, Rood B, Kamani N, Lafond D, Perez-Albuerne E, Loechelt B, Packer RJ, MacDonald TJ (2007) Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 48: 278-284. doi: 10.1002/pbc.20781 (Pubitemid 46238517)
19. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23: 7621-7631 (Pubitemid 46291826)
20. Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P, Albright AL, Wisoff JH, Milstein JM, Allen JC, Finlay JL et al (1994) Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 12: 1607-1615 (Pubitemid 24244996)
21. Kim SY, Sung KW, Hah JO, Yoo KH, Koo HH, Kang HJ, Park KD, Shin HY, Ahn HS, Im HJ, Seo JJ, Lim YJ, Lee YH, Shin HJ, Lim DH, Cho BK, Ra YS, Choi JU (2010) Reduced-dose craniospinal radiotherapy followed by high-dose chemotherapy and autologous stem cell rescue for children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor. Korean J Hematol 45: 120-126
22. Massimino M, Gandola L, Barra S, Giangaspero F, Casali C, Potepan P, Di Rocco C, Nozza P, Collini P, Viscardi E, Bertin D, Biassoni V, Cama A, Milanaccio C, Modena P, Balter R, Tamburrini G, Peretta P, Mascarin M, Scarzello G, Fidani P, Milano GM, Sardi I, Genitori L, Garre ML (2010) Infant ependymoma in a 10 year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherapy. Int J Radiat Oncol Biol Phys. doi: 10.1016/j.ijrobp.2010.02.048
23. Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leonard JR, Luchtman-Jones L, Rich KM, Grigsby PW, Lockett MA, Wahab SH, Simpson JR (2005) Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 61: 387-391. doi: 10.1016/j.ijrobp.2004.06.002 (Pubitemid 40164431)
24. Jaing TH, Wang HS, Tsay PK, Tseng CK, Jung SM, Lin KL, Lui TN (2004) Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. J Neurooncol 68: 255-261
25. Zacharoulis S, Moreno L (2009) Ependymoma: an update. J Child Neurol 24: 1431-1438. doi: 10.1177/0883073809339212
26. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA (2009) Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 10: 258-266
27. MacDonald SM, Safai S, Trofimov A, Wolfgang J, Fullerton B, Yeap BY, Bortfeld T, Tarbell NJ, Yock T (2008) Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 71: 979-986. doi: 10.1016/j.ijrobp.2007.11.065
28. Kano H, Niranjan A, Kondziolka D, Flickinger JC, Lunsford LD (2009) Outcome predictors for intracranial ependymoma radiosurgery. Neurosurgery 64: 279-287. doi: 10.1227/01.neu.0000338257. 16220.f7
29. Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ (2008) The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol 21: 165-177. doi: 10.1038/modpathol.3800999 (Pubitemid 351172168)
30. Zamecnik J, Snuderl M, Eckschlager T, Chanova M, Hladikova M, Tichy M, Kodet R (2003) Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol 16: 980-991. doi: 10.1097/01.mp.0000087420.34166.b6 (Pubitemid 37280813)
31. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P (2006) Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12: 2070-2079. doi: 10.1158/1078-0432.ccr-05-2363
32. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003. doi: 10.1056/NEJMoa043331 (Pubitemid 40349502)
33. Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F (2010) Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors- towards individualized tumor treatment? Neuro Oncol 12: 490-499. doi: 10.1093/neuonc/nop071